Features of transfusion therapy in hematopoietic stem cell transplantation
https://doi.org/10.24884/1607-4181-2016-23-4-61-65
Abstract
The aim of the research is to identify factors influencing the safety and efficacy of the transfusion therapy with hematopoietic stem cell transplantation (HSCT). From January 1 to December 31, 2015, 329 patients with hematologic diseases and malignancies who had undergone 367 HSCT were included into the study. Transfusion therapy was conducted in 345 HSCT – 94 % of cases. Totally, 9074 cases of transfusion of blood components were recorded: red blood cellcontaining – 2378 (26.2 %), plateletcontaining – 6255 (68.9 %), fresh frozen plasma – 441 (4.9 %). АВ0incompatibility between the donor and recipient was determined in 60.4 % of cases (n=154) in HSCT from allogeneic donor. Acute «graft versus host disease» was observed in 34.9 % of cases (n=89). Hemorrhagic complications were in 46 cases (12.5 %), mainly nasal, gastrointestinal bleeding and hemorrhagic cystitis. Pprevention and treatment of anemic and hemorrhagic complications in HSCT requires longterm and massive transfusion therapy with the availability of АВ0-incompatibility. The use of leukofiltrated, γ - or x-ray irradiated, individually and immunologically compatible blood components can reduce the risk of development of acute and delayed transfusion reactions in HSCT.
About the Authors
M. A. Kucher
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
D. E. Pevtcov
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
M. A. Estrina
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
N. E. Ivanova
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
O. A. Makarenko
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
B. A. Barishev
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
B. V. Afanasyev
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
References
1. Балашов Д. Н., Трахтман П. Е. Особенности проведения трансфузионной терапии у пациентов после трансплантации гемопоэтических стволовых клеток: обзор литературы // Онкогематология. – 2013. – № 3. – С. 42–47.
2. Борисова Е. О. Побочные эффекты системной глюкокортикостероидной терапии // Пульмонол. и аллергол. - 2004. – № 3. – С. 14–18.
3. Зубаровская Л. С., Фрегатова Л. М., Афанасьев Б. В. Трансплантация гемопоэтических стволовых клеток при гемобластозах // Клин.онкогематол. / под ред. М. А. Волковой. – М., 2001. – С. 479–494.
4. Кривов Ю. И., Торгунаков А. П., Рудаев В. И. и др. Переливание крови, ее компонентов и препаратов / под ред. дра мед.наук, проф. А. П. Торгунакова. – Кемерово: КемГМА, 2007. – 100 с.
5. Приказ Российской ассоциации трансфузиологов «Об утверждении Правил назначения компонентов крови» от 03 сент. 2007 г. № 10. URL:http://www.transfusion.ru/2007/09041.html (дата обращения 14.07.2016).
6. Шабалин В. Н., Серова Л. Д. Клиническая иммуногематология. – Л.: Медицина, 1988. – 312 с.
7. Booth G. S. ClinicalguidetoAB0incompatible allogeneic stem cell transplantation/ G. S. Booth, E. A.Gehrie, C. D. Bolan, B. N. Savani // Biol. Blood Marrow Transplant. – 2013. – Vol. 13. – P. 1152–1158.
8. Ferrara J. L. Graftversushostdisease / J. L. Ferrara, J. E. Levine, P. Reddy, E. Holler // Lancet. – 2009. – Vol. 373. – № 9674. – P. 1550–1561.
9. Gindina T., Mamaev N., Alyanskiy A. et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with KMT2A (MLL)related leukemia, depending on number of transplanted CD34+ cells // Bone Marrow Transplant. – 2015. – Vol. 50. – P. 481.
10. Gratwohl A. et al. Hematopoietic stem cell transplantation: a global perspective // JAMA. – 2010. – Vol. 303. – № 16. – P. 1617–1624.
11. Maziarz R. T., Slater S. Blood and marrow transplant handbook. Comprehensive guide for patient care // Springer. – 2011. – P. 1–324.
12. Rowley S. D., Donato M. L., BhattacharyyaP. Red blood cellincompatible allogeneic hematopoietic progenitor cell transplantation // Bone Marrow Transplantation. – 2011. – № 46. – P. 1167–1185.
13. Tomblyn M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective // Biol. Blood Marrow Transplant. – 2009. – Vol. 15. – P. 1143–1238.
14. Trottier B. J., Burns L. J., DeFor T. E. et al. Association of iron overload with allogeneic hematopoietic stem cell transplantation outcomes: a prospective cohort study using R2-MRI – measured liver iron content // Blood. – 2013. – Vol. 122. – P. 1678–1684.
Review
For citations:
Kucher M.A., Pevtcov D.E., Estrina M.A., Ivanova N.E., Makarenko O.A., Barishev B.A., Afanasyev B.V. Features of transfusion therapy in hematopoietic stem cell transplantation. The Scientific Notes of the Pavlov University. 2016;23(4):61-65. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-4-61-65
Views:
1027
Email this article 